Grwoth inhibition of mouse MXT mammary tumor by the luteinizing hormone-releasing hormone antagonist SB-75

Bela Szende, Gorden Srkalovic, Kate Groot, Karoly Lapis, Andrew V. Schally

Research output: Contribution to journalArticlepeer-review

59 Scopus citations

Abstract

Female BDF1 mice bearing MXT mammary adenocarcinomas were treated for 3 weeks with the luteinizing hormone-releasing hormone (LH-RH) antagonist [Ac-D-Nal(2)1, D-Phe(4Cl)2, D-Pal(3)3, D-Cit6, D-Ala10]-LH-RH (SB-75), with the agonist D-Trp6-LH-RH, with tamoxifen (5 μg per animal per day subcutaneously), with the combination of D-Trp6-LH-RH and tamoxifen, or by surgical ovariectomy. SB-75 and D-Trp6-LH-RH were administered in the form of microcapsules releasing 25 μg/ day. The reduction in tumor weights after treatment with SB-75, D-Trp6-LH-RH, D-Trp6-LH-RH plus tamoxifen, or ovariectomy was 84%, 64%, 33%, and 67%, respectively. Tamoxifen alone was ineffective. Histologically, the regressive changes in the treated tumors were characteristic of apoptosis (programmed cell death). In view of its potency and its immediate inhibitory effect, the LH-RH antagonist SB-75 should be considered as a possible new hormonal agent for the treatment of breast cancer.

Original languageEnglish (US)
Pages (from-to)513-517
Number of pages5
JournalJournal of the National Cancer Institute
Volume82
Issue number6
DOIs
StatePublished - Mar 21 1990
Externally publishedYes

ASJC Scopus subject areas

  • Oncology
  • Cancer Research

Fingerprint Dive into the research topics of 'Grwoth inhibition of mouse MXT mammary tumor by the luteinizing hormone-releasing hormone antagonist SB-75'. Together they form a unique fingerprint.

Cite this